Iovance Biotherapeutics Q3 EPS $(0.05) Beats $(0.09) Estimate, Sales $121.469M Beat $115.982M Estimate
Benzinga Newsdesk 2 hours ago
NewsEarningsEarnings Beats
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.09) by 37.5 percent. This is a 80 percent increase over losses of $(0.25) per share
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.09) by 37.5 percent. This is a 80 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $121.460 million which beat the analyst consensus estimate of $115.982 million by 4.72 percent. This is a 80.06 percent increase over sales of $67.455 million the same period last year.